Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinationsResearch in context

Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinationsResearch in context

Summary: Background: Conventional dendritic cells (cDCs), are central to antitumour immunity, but their low prevalence in tumours limits the efficacy of immunotherapies. FLT3L is a key growth factor regulating cDCs development in the bone marrow. It expands cDCs when administered exogenously, favou...

Whakaahuatanga katoa

I tiakina i:
Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua: Jérémie Decalf, Evangeline Toy, Dongping He, Radhika Kenkre, Amy M. Berkley, Devon Wong, Mandy Kwong, Yee-Seir Kee, Yue Sun, Srividya Myneni, Xiangdan Wang, Ahmad Ebtikar, Anthony Ancheta, Yanli Yang, Hok Seon Kim, Nga Tang, Debarko Banerji, Elaine Mai, Pranay Dogra, Meredith McLerie, Alan G. Gutierrez, Geraldine Strasser, Gautham K. Rao, Matt Betzenhauser, Wilson Phung, Peter Day, Wendy Sandoval, Ayse Meric Ovacik, Pamela Chan, Shomyseh Sanjabi, Laetitia Comps-Agrar, Sivan Cohen, James A. Ernst, Greg A. Lazar, Christopher C. Kemball, Iraj Hosseini, Yichin Liu, Jill M. Schartner, Travis W. Bainbridge, Christine Moussion
Hōputu: Tuhinga
Reo:Ingarihi
I whakaputaina: Elsevier 2025-08-01
Rangatū:EBioMedicine
Ngā marau:
Dendritic cells
Cancer immunotherapy
FLT3L
Innate immunity
Adaptive immunity
Urunga tuihono:http://www.sciencedirect.com/science/article/pii/S235239642500266X
Tags: Tāpirihia he Tūtohu
No Tags, Be the first to tag this record!

Ngā tūemi rite